ES2116594T3 - Ansamicinas biciclicas y su uso como agentes antitumorales. - Google Patents

Ansamicinas biciclicas y su uso como agentes antitumorales.

Info

Publication number
ES2116594T3
ES2116594T3 ES94913896T ES94913896T ES2116594T3 ES 2116594 T3 ES2116594 T3 ES 2116594T3 ES 94913896 T ES94913896 T ES 94913896T ES 94913896 T ES94913896 T ES 94913896T ES 2116594 T3 ES2116594 T3 ES 2116594T3
Authority
ES
Spain
Prior art keywords
ansamicins
bicyclic
antitumoral agents
agents
antitumoral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94913896T
Other languages
English (en)
Inventor
Rodney C Schnur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2116594T3 publication Critical patent/ES2116594T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

ESTA INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA (I) EN DONDE R{SUP, 1}, R{SUP, 2}, R{SUP, 3} Y X SON SEGUN SE DEFINE EN LA DESCRIPCION. TALES COMPUESTOS SON UTILES COMO INHIBIDORES DE LOS ONCOGENES Y COMO AGENTES ANTITUMORALES.
ES94913896T 1993-04-07 1994-03-14 Ansamicinas biciclicas y su uso como agentes antitumorales. Expired - Lifetime ES2116594T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/044,521 US5387584A (en) 1993-04-07 1993-04-07 Bicyclic ansamycins

Publications (1)

Publication Number Publication Date
ES2116594T3 true ES2116594T3 (es) 1998-07-16

Family

ID=21932854

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94913896T Expired - Lifetime ES2116594T3 (es) 1993-04-07 1994-03-14 Ansamicinas biciclicas y su uso como agentes antitumorales.

Country Status (10)

Country Link
US (1) US5387584A (es)
EP (1) EP0693073B1 (es)
JP (1) JP2722280B2 (es)
AT (1) ATE166877T1 (es)
CA (1) CA2160137C (es)
DE (1) DE69410790T2 (es)
DK (1) DK0693073T3 (es)
ES (1) ES2116594T3 (es)
FI (1) FI106028B (es)
WO (1) WO1994022867A1 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852496B1 (en) * 1997-08-12 2005-02-08 Oregon Health And Science University Methods of screening for agents that promote nerve cell growth
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
EP1098666B1 (en) 1998-07-17 2013-01-16 The United States of America, represented by the Secretary, Department of Health and Human Services Water-soluble drugs and methods for their production
US6747055B1 (en) * 1998-07-17 2004-06-08 The United States Of America As Represented By The Department Of Health And Human Services Water-soluble drugs and methods for their production
ID29393A (id) * 1998-12-07 2001-08-30 Ecosmart Technologies Inc Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
EP1322307B1 (en) * 2000-07-28 2011-09-28 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
AU2877102A (en) * 2000-11-02 2002-05-15 Sloan Kettering Inst Cancer Small molecule compositions for binding to hsp90
CN1473055A (zh) 2000-11-02 2004-02-04 ˹¡-�����ְ�֢�о��� 通过使用hsp90抑制剂提高细胞毒剂效力的方法
US20060079493A1 (en) * 2001-03-01 2006-04-13 Lawrence Fritz Methods for treating genetically- defined proliferative disorders with hsp90 inhibitors
US7825094B2 (en) * 2001-05-23 2010-11-02 Sloan-Kettering Institute For Cancer Research Method of treatment for cancers associated with elevated HER 2 levels
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
EP1923061A1 (en) 2001-09-24 2008-05-21 Conforma Therapeutic Corporation Process for preparing 17-Allyl amino geldanamycin (17-AAG) and other ansamycins
DE60225307T2 (de) * 2001-09-24 2009-03-19 Conforma Therapeutics Corp., San Diego Verfahren zur herstellung von 17-allyl-amino-geldanamycin (17-aag) und anderer ansamycine
US7261875B2 (en) 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
ATE433961T1 (de) * 2002-02-08 2009-07-15 Conforma Therapeutics Corp Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften
EP1492522A4 (en) * 2002-04-10 2009-01-14 Conforma Therapeutics Corp ANSAMYCIN FORMULATIONS AND METHODS OF MAKING AND USING THE SAME
US20060148776A1 (en) * 2003-03-13 2006-07-06 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050054625A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US7691838B2 (en) * 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US20050054589A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
US7241754B2 (en) * 2003-06-13 2007-07-10 Kosan Biosciences, Inc. 2-Desmethyl ansamycin compounds
CN100404029C (zh) * 2003-09-25 2008-07-23 中国医学科学院医药生物技术研究所 格尔德霉素(c-3559)在制备疱疹病毒生殖道感染药物中的应用
US6870049B1 (en) 2003-11-12 2005-03-22 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6875863B1 (en) 2003-11-12 2005-04-05 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6855705B1 (en) 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US20060019941A1 (en) * 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
CN102643233B (zh) 2003-12-23 2015-11-25 无限发现公司 用于治疗癌症的包含苯醌的安沙霉素类似物
WO2005072766A2 (en) * 2004-01-27 2005-08-11 Boys Town National Research Hospital Peptides that bind to hsp90 proteins
US20080171687A1 (en) * 2004-09-16 2008-07-17 Abraxis Bioscience, Inc. Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs
US20060067953A1 (en) * 2004-09-29 2006-03-30 Conforma Therapeutics Corporation Oral pharmaceutical formulations and methods for producing and using same
JP2008534609A (ja) 2005-03-30 2008-08-28 コンフォーマ・セラピューティクス・コーポレイション Hsp90阻害剤としてのアルキニルピロロピリミジンおよび関連類似体
BRPI0608661A2 (pt) * 2005-04-07 2010-01-19 Conforma Therapeutics Corp formulaÇço farmacÊutica, uso de formulaÇço farmacÊutica, e, mÉtodo de preparaÇço de uma formulaÇço farmacÊutica
RU2007144195A (ru) * 2005-04-29 2009-06-10 Козан Байосайенсиз Инкорпорейтед (Us) Способ лечения множественной миеломы с использованием 17-aag или 17-ag или пролекарства любого из них
MX2007013499A (es) * 2005-04-29 2008-01-24 Kosan Biosciences Inc Metodo para tratar mieloma multiple utilizando 17-aag o 17-ag o un profarmaco de ya sea 17-aag o 17-ag en combinacion con un inhibidor de proteasoma.
US20080032719A1 (en) * 2005-10-01 2008-02-07 Outland Research, Llc Centralized establishment-based tracking and messaging service
WO2007002093A2 (en) * 2005-06-21 2007-01-04 Infinity Discovery, Inc. Ansamycin formulations and methods of use thereof
WO2007035963A2 (en) * 2005-09-23 2007-03-29 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
EP1954265A2 (en) * 2005-12-01 2008-08-13 Conforma Therapeutics Corporation Compositions containing ansamycin
EP2054506A1 (en) 2006-08-15 2009-05-06 Agency for Science, Technology and Research Mesenchymal stem cell conditioned medium
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
WO2008094438A1 (en) 2007-01-26 2008-08-07 Kosan Biosciences Incorporated Macrolactams by engineered biosynthesis
US20080255080A1 (en) * 2007-04-12 2008-10-16 Wright James L Hydroquinone Ansamycin Formulations
AU2008240153B2 (en) * 2007-04-12 2013-01-31 Joyant Pharmaceuticals, Inc. SMAC mimetic dimers and trimers useful as anti-cancer agents
JP2011501731A (ja) * 2007-09-10 2011-01-13 ユニバーシティ オブ マサチューセッツ ミトコンドリア標的化抗腫瘍剤
US7960420B2 (en) * 2007-12-21 2011-06-14 Joyant Pharmaceuticals, Inc Diazonamide analogs with improved solubility
SI2254586T1 (sl) 2008-02-22 2015-07-31 Agency For Science, Technology And Research (A*Star) Delci mezenhimske matične celice
US8716018B2 (en) 2008-03-17 2014-05-06 Agency For Science, Technology And Research Microcarriers for stem cell culture
AU2009243056B2 (en) * 2008-04-29 2015-05-14 Joyant Pharmaceuticals, Inc. Indoline anti-cancer agents
US8153619B2 (en) * 2008-05-22 2012-04-10 Joyant Pharmaceuticals, Inc. Diazonamide analogs
EP2348845A4 (en) 2008-10-15 2013-01-23 Infinity Pharmaceuticals Inc ANSAMYCIN HYDROQUINONE COMPOSITIONS
EP2471918A4 (en) 2009-09-29 2013-06-05 Takeda Pharmaceutical SCREENING PROCESS
EP2784076A1 (en) 2009-10-28 2014-10-01 Joyant Pharmaceuticals, Inc. Dimeric SMAC mimetics
SG2014010698A (en) 2009-11-02 2014-05-29 Agency Science Tech & Res Methods of monitoring cellular states
SG183579A1 (en) 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
RU2608308C2 (ru) 2011-04-22 2017-01-17 Джоянт Фармасьютикалс, Инк. Аналоги диазонамида
EP3795694A3 (en) 2012-10-02 2021-06-23 The General Hospital Corporation d/b/a Massachusetts General Hospital Methods relating to dna-sensing pathway related conditions
US9993460B2 (en) 2013-07-26 2018-06-12 Race Oncology Ltd. Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
WO2015140005A1 (en) 2014-03-19 2015-09-24 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Method of generation of pluripotent cells
US20190231694A1 (en) 2016-10-12 2019-08-01 Agency For Science, Technology And Research Method for lyophilising an exosome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987035A (en) * 1974-04-05 1976-10-19 University Of Illinois Foundation Biologically active compounds
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug

Also Published As

Publication number Publication date
DE69410790T2 (de) 1998-10-01
ATE166877T1 (de) 1998-06-15
EP0693073B1 (en) 1998-06-03
JPH08503960A (ja) 1996-04-30
US5387584A (en) 1995-02-07
FI941580A (fi) 1994-10-08
FI941580A0 (fi) 1994-04-06
CA2160137A1 (en) 1994-10-13
JP2722280B2 (ja) 1998-03-04
DE69410790D1 (de) 1998-07-09
WO1994022867A1 (en) 1994-10-13
FI106028B (fi) 2000-11-15
CA2160137C (en) 1999-02-09
EP0693073A1 (en) 1996-01-24
DK0693073T3 (da) 1998-10-12

Similar Documents

Publication Publication Date Title
ES2116594T3 (es) Ansamicinas biciclicas y su uso como agentes antitumorales.
NO20001940D0 (no) Bicykliske kinase-inhibitorer
DE69825048D1 (de) Analoga von duocarmycin and cc-1065
PT970095E (pt) Novos inibidores benzimidazole de frutose-1,6-bisfosfatase
LV12358A (lv) 7-(Aizvietoti)-9-(aizvietoti glicil)-amido-6-demetil-6-deoksitetraciklini
ES2138622T3 (es) Derivados de mercaptoacetilamido piridazo(1,2-a)(1,2)diazepina utilizados como inhibidores de encefalinasa y eca.
ES2184797T3 (es) Uso de antagonistas de serotonina (5ht3) para el tratamiento de la fibromialgia.
ATE271058T1 (de) Mycophenol bisphosponatverbindungen
ATE217629T1 (de) Phosphonooxymethyl oder methylthiomethylether von taxanderivaten als antitumormittel
FI970810A0 (fi) Ionipolymeerejä sisältäviä biologisesti aktiivisia anioneja
MX9302906A (es) Derivados de mercaptoacetilamida novedosos utiles como inhibidores de la encefalinasa.
DK0873340T3 (da) Heterocyklisk substituerede cyclopentanforbindelser
DK0705100T3 (da) Terapeutiske substituerede guanidiner
MY111201A (en) New imidazopyridines
BG99177A (en) New 7 -substituted-4-aza-5 - cholestanones as inhibitors of 5 - reductase
MX9205678A (es) Heteroarilaminas como nuevos inhibidores de la acetilcolinesterasa.
MX9305092A (es) Nuevas 4, 5-dihidro-4-oxo-pirrolo(1, 2-alquinoxalinas y sus correspondientes aza-analogos y procedimiento para su elaboracion.
ES2139669T3 (es) Nuevos derivados triciclicos de indan-2-mercaptoacetilamida 2-substituidos utiles como inhibidores de la encefalinasa.
ZA945246B (en) Novel 9-N-Bicyclic nucleoside agents useful as selective inhibitors of proinflammatory cytokines
ES2179864T3 (es) 4-benzoil-isoxazoles y su uso como herbicidas.
ATE165594T1 (de) Triarylethylenderivate zur therapeutischen verwendung
NO20002191L (no) Dofetilid polymorfer
DE69418050D1 (de) Antivirale analoge von difluorostaton
DK1017377T3 (da) Anvendelse af 6,7-substituerede 2-aminotetraliner til behandling af af cytokin fremkaldte inflammatoriske tilstande
GR1001385B (el) Παράγωγα ιμιδαζο 1,2-α (πυρρολο,?ειενο η φουρανο) 3,2-d αζεπίνης συν?έσεις και μέ?οδοι χρήσεως.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 693073

Country of ref document: ES